3M India Ltd share Price Today

Industrial Machinery company 3M India announced Q3FY24 results:

Consolidated Q3FY24 vs Q3FY23:
- Sales & other operating Income: Rs 1,006 crore in Q3FY24, up by 1% from Rs 993 crore in Q3FY23.
- Other income: Rs 17 crore in Q3FY24, up by 42% from Rs 12 crore in Q3FY23.
- EBITDA: Rs 195 crore in Q3FY24, a 7% increase from Rs 183 crore in Q3FY23.
- PBT: Rs 181 crore in Q3FY24, up by 8% from Rs 167 crore in Q3FY23.
- PAT: Rs 135 crore in Q3FY24, showing an 8% increase from Rs 125 crore in Q3FY23.

Consolidated Q3FY24 vs Q2FY24:
- Sales & other operating income: Rs 1,006 crore in Q3FY24, down by 3% from Rs 1,040 crore in Q2FY24.
- Other income: Rs 17 crore in both quarters, no change.
- EBITDA: Rs 195 crore in Q3FY24, a 7% decrease from Rs 210 crore in Q2FY24.
- PBT: Rs 181 crore in Q3FY24, an 8% decrease from Rs 196 crore in Q2FY24.
- PAT: Rs 135 crore in Q3FY24, showing an 8% decrease from Rs 146 crore in Q2FY24.

Standalone Q3FY24 vs Q3FY23:
- Sales & other operating income: Rs 942 crore in Q3FY24, up by 1% from Rs 932 crore in Q3FY23.
- Other income: Rs 14 crore in Q3FY24, up by 27% from Rs 11 crore in Q3FY23.
- EBITDA: Rs 181 crore in Q3FY24, a 9% increase from Rs 166 crore in Q3FY23.
- PBT: Rs 167 crore in Q3FY24, up by 11% from Rs 151 crore in Q3FY23.
- PAT: Rs 125 crore in Q3FY24, showing an 11% increase from Rs 113 crore in Q3FY23.

Standalone Q3FY24 vs Q2FY24:
- Sales & other operating income: Rs 942 crore in Q3FY24, down by 3% from Rs 975 crore in Q2FY24.
- Other income: Rs 14 crore in Q3FY24, down by 7% from Rs 15 crore in Q2FY24.
- EBITDA: Rs 181 crore in Q3FY24, a 6% decrease from Rs 193 crore in Q2FY24.
- PBT: Rs 167 crore in Q3FY24, a 7% decrease from Rs 179 crore in Q2FY24.
- PAT: Rs 125 crore in Q3FY24, showing a 7% decrease from Rs 134 crore in Q2FY24.

Commenting on the consolidated financial result for the quarter and nine months ended December 31, 2023, Ramesh Ramadurai, Managing Director of 3M India, said, “The Company delivered 1.3% sales growth in the current quarter versus prior year, and a decline of 3.3% on a sequential basis. The Company delivered an 8.3% growth in Proft Before Tax versus prior year with PBT margin of 17.7%. For the nine months ended December 31, 2023, the Company delivered sales growth of 6.2% and PBT growth of 30.1%. Business trends broadly remained steady versus the previous quarter, though some softness was observed in the Health Care segment.”

Result PDF